Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance

Uro-Oncology

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Eur Urol.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y

doi: 10.1016/j.eururo.2018.01.017.

Uro-Oncology

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

BJU Int.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ

doi: 10.1111/bju.13676.

Uro-Oncology

A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings

doi: 10.1111/bju.15048.

Uro-Oncology

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

J Urol.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW

doi: 10.1016/j.juro.2018.07.065.

Uro-Oncology

The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance

J Urol.

Gregg JR, Surasi DS, Childs A, Moll N, Ward JF, Kim J, Daniel CR, Logothetis C, Bathala T, Davis JW

doi: 10.1097/JU.0000000000001321.

Uro-Oncology

Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series

Prostate.

Fernández-Conejo G, Hernández V, Guijarro A, de la Peña E, Inés A, Pérez-Fernández E, Llorente C

doi: 10.1002/pros.23933.

Uro-Oncology

Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance

BJU Int.

Shapiro DD, Ward JF, Lim AH, Nogueras-González GM, Chapin BF, Davis JW, Gregg JR

doi: 10.1111/bju.15100.

Uro-OncologyPregnancy and Childbirth

Qualitative study on decision-making by prostate cancer physicians during active surveillance

BJU Int.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E

doi: 10.1111/bju.13651.

Further Publications Urology

Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study

Prostate Cancer Prostatic Dis

Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, Yee CH, Teoh JY, Hou SM, Roobol M, Ng CF, Chiu PK

doi: 10.1038/s41391-021-00444-y

Related content

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings

Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS)

The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance

Prostate cancer adverse pathology reclassification in patients undergoing active surveillance in a long-term follow-up series

Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance

Qualitative study on decision-making by prostate cancer physicians during active surveillance

Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study